The share price of Ocular Therapeutix Inc (NASDAQ: OCUL) increased 2.71% to $19.68 in after-market trade. OCUL stock gained 22.74 percent to close at $19.16 on Thursday. Ocular stock price has moved up by 21.96% in the past week and has increased by 213.07% in the past 12 months. The development came after the release date of financial details and a series of presentations during a research event resulted in a surge in OCUL stock.
What did the OCUL share?
Based on its proprietary formulation technology, Ocular Therapeutix develops and commercializes bioresorbable hydrogel-based therapies for diseases and conditions of the eye. In the treatment of eye inflammation and pain following ophthalmic surgery, DEXTENZA, the company’s first commercial drug product, is FDA-approved. An additional approved indication of DEXTENZA is ocular itching in association with seasonal allergic conjunctivitis for which a PDUFA target date has been set of October 18, 2021.
Yesterday, the Ocular Therapeutix announced it will be presenting multiple scientific studies at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. The ARVO Annual Meeting 2021 will be moved to a virtual format, and a number of video presentations will be available to watch online at ARVOLearn on May 1, 2021.
Release of quarterly results:
Furthermore, Ocular Therapeutix (OCUL) announced that its first-quarter financial results were expected to be released on Wednesday, May 5, 2021. OCUL management will conduct a conference call and live webcast following the release of the earnings report via wire services at 4:30 eastern time. This webcast involves a discussion of OUCL’s financial results and a business update from OCUL’s management.